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Bullet points 
 Widespread non-arthritic pain is a common concurrent disorder in patients with 
psoriatic arthritis, regardless of fibromyalgia. 
 Widespread non-arthritic pain is associated with worse patient-reported and 
composite psoriatic arthritis activity measures but not with higher disease burden 
evaluated by clinical- and ultrasound examination. 
 A condition of widespread non-arthritic pain at baseline was strongly associated with 
failure to fulfil the Minimal Disease Activity Criteria following immunomodulatory 
therapy. 
 
ABSTRACT 
Objective: To study the prognostic value of widespread pain and of musculoskeletal 
ultrasound (US) examination for subsequent treatment outcomes in patients with psoriatic 
arthritis (PsA). 
 
Methods: An exploratory prospective cohort study enrolled PsA patients initiating 
biologic/conventional synthetic disease modifying anti-rheumatic drugs in routine care. 
Clinical-, US- and patient-reported measures were retrieved at baseline and after 4 months. 
Widespread non-arthritic pain (WP) was defined as Widespread Pain Index ≥4 with pain in 
≥4/5 regions. PsA activity by US was defined as colour Doppler (CD) (yes/no) in selected 
entheses, joints or tendons. Main response criteria included American College of 
Rheumatology 20% (ACR20), Disease Activity in Psoriatic Arthritis 50% (DAPSA50), and 
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Minimal Disease Activity (MDA). The primary analyses were age-and gender adjusted logistic 
regression. 
 
Results: WP was present in 24 (35%) of 69 included patients, and associated with worse 
patient-reported and composite baseline measures while US and other objective findings 
were similar to patients without WP. The odds of 4-months MDA were significantly greater 
for patients enrolled without WP (OR=18.43 [95% CI: 1.51-224.41], p=0.022), while WP did 
not impair other response measures. Patients with baseline CD activity (n=42 [61%]) had 
worse objective PsA burden but their chance of treatment response was comparable to 
those without CD. 
 
 Conclusions: More than one-third of PsA patients presented with widespread non-arthritic 
pain, which was associated with worse patient-reported scores and failure to achieve MDA 
following cs/bDMARD therapy.  PsA activity by colour Doppler ultrasound had no influence 
on subsequent treatment response in this PsA cohort. 
 
INTRODUCTION 
Pain is a key manifestation of psoriatic arthritis (PsA), and a core outcome in trials and 
observational studies according to the PsA Core Outcome Set (COS) endorsed by the group 
of Outcome Measures in Rheumatology (OMERACT). (1) However, little focus has been on 
the prognostic value of pain mechanisms for treatment effectiveness. Recent studies have 
reported persistent pain in >50% of PsA patients in spite of conventional synthetic or 
biologic disease modifying therapy (cs/bDMARD) and well-controlled inflammation. (2,3) 
Furthermore, patients often report non-nociceptive pain features such as allodynia and 
hyperalgesia. These observations could indicate contributions from central sensitization. (3–
5) 
Central sensitization is a normal, physiological phenomenon in relation to acute 
tissue damage where it accounts for secondary hyperalgesia and allodynia in the proximity 
of the injured site. However, as shown in rheumatoid arthritis (RA) and osteoarthritis (OA), 
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(6,7) central sensitization can sometimes outlast inflammation and cause persistent and 
widespread pain. Underlying reasons for this phenomenon possibly involve inflammatory-,  
genetic- and psychological factors. (8,9) Central sensitization is by many perceived as a 
continuum. (5) The upper end is represented by fibromyalgia characterized by widespread 
pain, cognitive, emotional and physical disturbances. (8) Fibromyalgia exists  in 16-22% of 
PsA patients and seems to bias the evaluation of PsA activity. (10,11) Based on the 
continuum theory,  central sensitization may contribute to persistent pain in PsA – 
regardless of fibromyalgia – and influence measures of PsA activity and treatment response. 
Central sensitization is not easily measured in routine care, however its key symptom, 
widespread non-arthritic pain, can be assessed by the widespread pain index (WPI). (8) 
Musculoskeletal ultrasound (US) can dynamically visualize pathophysiology in 
arthritic diseases, including PsA. (12,13) Hypothetically, US could prove useful in 
determining if widespread pain is caused by central sensitization uncoupled from 
inflammatory activity or  by diffuse, multisite PsA activity that warrants anti-rheumatic 
treatment. Besides, US could  be a prognostic factor for treatment outcome by identifying 
patients with high inflammatory load and great need for  immunomodulatory therapy. A 
prognostic value of US has been shown in RA but is unclarified in PsA. (13–17) 
Our primary aim was to explore the presence of 1) widespread, non-arthritic pain 
(WP) measured by the WPI and 2) inflammatory activity evaluated by colour Doppler US, in 
patients with PsA. Specifically, we aimed to study the relationship between these factors, 
and their prognostic value for 4-month cs/bDMARD response. A second aim was to study if 
WP represents a chronic condition or is reversed during immunomodulatory therapy. 
Finally, we aimed to explore the prognostic value of secondary pain- and ultrasound 
measure for treatment response.  
 
METHODS 
Design and period 
We performed a prospective cohort study according to a published protocol elaborated in 
collaboration with patient-research partners from Denmark and abroad. (18) Study findings 
are reported according to Strengthening The Reporting of OBservational Studies in Epi-
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demiology (STROBE) guidelines. (19) The study was registered at clinicaltrials.gov 
(NCT02572700), and approved by the Danish ethics committee (H-15009080), and Data 
Protection Agency (2012-58-0004). Inclusion started September 17 2015, and ended June 1 
2017. No power calculation was performed due to the exploratory design, however we 
anticipated to include approximately 100 participants. 
 
Inclusion criteria 
We recruited PsA patients scheduled to start cs/bDMARDs (first line/add-on/switch) from 
rheumatology clinics in the Capital region of Denmark. To be included, patients had to sign 
an informed consent form, be ≥18 years old, fulfil Classification Criteria for PsA (CASPAR) 
(20) and present with peripheral PsA manifestations. Exclusion criteria were pregnancy, 
neurological disorders, and rheumatic inflammatory diseases besides PsA. Patients were 
non-eligible if they could not pause glucocorticoids, centrally acting drugs, and non-opioid 
analgesics at 21, 7 and 1 days before baseline, respectively. 
 
Time points and variables 
Baseline was defined as the time window from 14 days before until 7 days after treatment 
start. No washout period was required for those switching therapy. The follow-up date was 
4 months after baseline. Following information was collected at the study visits. 
Interview: Physician (PH or CB) collected information on socio-demography, psoriatic 
disease, medications, smoking, and body mass index (BMI).  
Patient reported measures of central pain sensitization: The WPI (0-19) (8) is a two-sided 
body diagram where patients mark all painful non-joint regions (7 day recall). Hence, the 
WPI measures both the number and distribution of painful sites. The WPI was developed for 
diagnosing the widespread pain component of fibromyalgia. (8) Inspired by the use of WPI 
in fibromyalgia, we interpreted symptoms of central sensitization as: WPI ≥4 and pain in 
≥4/5 predefined regions. (8) 
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The PainDETECT (21) PDQ (-1-38) was developed to identify neuropathic pain in low 
back pain patients but has been used to evaluate pain phenotypes across rheumatic 
diseases. (3,22) High PDQ scores have been associated with measures of central 
sensitization in fibromyalgia. (23) The PDQ score is based on patient’s description of pain; 
somatosensory symptoms, pain radiation and temporal characteristics, and thereby reflects 
nociceptive (PDQ score <13), unclear (PDQ score 13-18) or neuropathic (PDQ score >18) 
pain. 
Other questionnaires: Patients completed  Dermatology Life Quality Index (DLQI), (24) 
Psoriatic Arthritis Impact of Disease (PsAID), (25) Health Assessment Questionnaire 
Disability Index (HAQ-DI), (26) Bath Ankylosing Functional (BASFI) - and Disease Activity 
(BASDAI) Index, (27) MOS SF-36 questionnaire, (28) Generalized Anxiety Disorder 
questionnaire (GAD-10)  and numeric rating of fatigue (NRS fatigue), visual analogue scales 
(VAS) of pain and patient global. At follow-up, patients also completed a transition 
questionnaire regarding overall  improvement (yes/no). (18) 
Clinical examination:  Physicians (PH or CB) performed a 18 sites Tender Point Count (TPC), a 
66/68 swollen/tender joint count (SJC, TJC), the Psoriasis Area Severity Index  (PASI), the 
Spondyloarthritis Research Consortium of Canada enthesitis index (SPARCC), and counted 
psoriatic nails (0-20) and dactylitis (0-20). (18)  
Paraclinical measures: X-rays of hands and feet were analysed for structural PsA changes by 
a radiologist unaware of clinical findings. A blood test was drawn to measure C-reactive 
protein (CRP).  
Musculoskeletal US: US was performed the same day as clinical examinations by 
experienced sonographers (KE or LJ) using a General Electric E9 with a linear array matrix 
transducer (15 MHz frequency). Grey-scale and colour Doppler examinations included 26 
small and large joints (46 projections), extensor- and flexor tendons adjacent to the wrist 
and finger joints (32 projections), and 12 entheses. Scans were performed in longitudinal 
projections. For hands and feet, both dorsal and plantar projections were applied. 
Central/radial/ulnar projections of wrists and medial/lateral projections of the knees were 
performed. The US protocol is provided in File 1S.  
A third US expert (JGM), unaware of clinical findings, scored the US pathologies by stored 
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images and clips. Both semi-quantitative (0-3) and dichotomous (0/1) scores of Grey scale 
and colour Doppler findings were performed. (12,29)  
 
Prognostic factors of interest 
Primary factors:  
1) Widespread non-arthritic pain: Patients with baseline WPI ≥4 and pain in ≥4/5 regions 
were categorized as WP+, others as no-WP. (8) 
2) Inflammatory activity by colour Doppler: The sum of colour Doppler scores from joints 
(score 0-138), entheses (score 0-30) and tendons (score 0-32) was termed a ‘Global Active 
Ultrasound Score’ (GAUS) (score 0-200). The primary prognostic US factor was 
GAUS≥1/GAUS=0, i.e. presence/absence of colour Doppler activity.  
 
Secondary factors:  
Central sensitization: Based on previous studies, we also explored central sensitization as 1) 
PDQ score ≥13 i.e. non-nociceptive pain features  (21,23), 2) Tender Point Count (TPC) ≥8 i.e. 
widespread allodynia/hyperalgesia (30) and 3) a ratio of swollen/tender joints (SJ/TJ) <0.5. 
(31) 
US pathology: We arbitrarily defined secondary US measures as a Global Subacute 
Ultrasonic Score (GSAUS 0-204) and a Global Chronic Ultrasonic Score (GCUS, 0-312). GSAUS 
was the sum of the grey scale synovitis scores of joints (0-138) and tendons (0-32), entheses 
thickening (yes/no) (0-10), structural entheses changes (yes/no) (0-12) and of bursitis (0-12) 
(yes/no). GCUS was the sum score of erosions (0-138), osteophytes (0-138) and entheses 
calcifications (0-36). GSAUS and GCUS were handled as binary prognostic variables using the 
median value as cut-off (File 1S). 
 
Outcome measures and composite endpoints 
Treatment response after 4 months was assessed according to American College of 
Rheumatology 20% improvement (ACR20). (32) Secondary outcomes (assessed for WP and 
GAUS) included Minimal Disease Activity (MDA) (33) and 50% improvement in Disease 
activity index for Psoriatic Arthritis (DAPSA 50%), (34) and the  exploratory outcome 
‘Patient-Reported Improvement’ (yes/no) obtained from the transition questionnaire. (18) 
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Changes from baseline in composite indices including DAPSA, Disease Activity Score (DAS28-
CRP), (35) the modified Composite Psoriatic Disease Activity Index (mCPDAI) (36) and 
change in OMERACT PsA COS measures (1) (File 1S) were compared between groups. For 
mCPDAI, which was added to the analyses following peer review, we used a modified Leeds 
Enthesitis Index, where the medial femur condyle was replaced by fascia plantaris available 
from the protocolled SPARCC index.  
 
Statistical analyses 
 
A statistical analysis plan was prepared prior to data extraction (File 1S). All analyses were 
performed in R (version 3.3.3) by a biostatistician. Statistical significance was interpreted as 
p-values <0.05 (two-sided). Logistic regression analyses were performed to investigate the 
association between the prognostic variables and treatment response (yes/no). Odds ratios 
were reported as crude estimates (OR) and adjusted for gender and age (aOR). When we 
observed zero-event data in one study group and imbalances in patient numbers between 
study groups, we used a continuity correction that was inversely proportional to the relative 
size of the opposite of the study (37). Since asymptotic results can be unreliable when the 
distribution of the dichotomous data is sparse we applied the Fisher’s exact test to calculate 
the exact probability of the possible (2×2) table, enabling us to estimate the Wald test 
associated variance, corresponding to the ratio of its estimate (logOR) to its standard error. 
(38)  
Primary analyses included the intention-to-treat (ITT) population (non-responder 
imputation/baseline observation carried forward). Concordance statistics (the C-index), 
tested the models’ ability to distinguish  patients who will experience a response from those 
who will not. (39)   
The following additional analyses were performed:  
1)The prognostic value of WP and GAUS profiles for ACR20 response was analysed using 
data ‘as observed’ and ‘per protocol’ (i.e. patients with complete data who stayed in 
treatment). 
2) ∆COS measures at follow-up were compared for GAUS and WP categories by Student’s t-
test or Mann-Whitney U test, and secondly by Analysis of Covariance (ANCOVA) adjusting 
for baseline values.  
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3) The correlation between continuous WPI and GAUS, respectively, and ∆DAS28-CRP, 
∆DAPSA and ∆mCPDAI were analysed by scatter diagrams with Spearman Rank Correlation 
coefficients. Prediction ellipses were added to give a visual impression of the distribution of 
data with the center representing the sample mean. Skinny ellipses are seen when the 
correlation between variables is high. Following peer review, correlations between change 
in composite indices and ∆WPI were analysed. 
4) To explore if WP reflected a reversible state we analysed the agreement between WP 
category at baseline and follow-up using kappa statistics.[2]  
5) Fulfilment of ≥11/18 tender points (per 1990-fibromyalgia criteria) was assessed for WP 
groups. 
6) The intra/inter reliability of GAUS, GSAUS and GCUS was calculated and appeared 
excellent according to Intraclass Correlation Coefficients (ICC 2,1) (File 1S), exceeding the 
predefined 0.75 cut-off (Table 1S). 
 
RESULTS 
Out of 123 screened patients we included 69, and 24 (35%) of these fulfilled the 
widespread, non-arthritic pain criterion (WP+) as illustrated in Figure 1.  
 
Baseline characteristics for the WP and GAUS profiles: Compared to those without WP, 
patients with WP+ presented with worse pain, fatigue and health-related quality of life, and 
more tender joints- and entheses as shown in Table 1. The WP+ group had significantly 
higher composite disease activity scores (DAPSA, DAS28-CRP and mCPDAI), while clinician-
reported, radiographic and ultrasound findings were comparable between WP groups (Table 
1). Colour Doppler activity (GAUS≥1) was present in 13 (54 %) of WP+ and 29 (64 %) of no-
WP patients (p=0.566). No differences in sociodemographic, BMI, DMARDs or other 
background characteristics existed between WP groups, except for greater use of analgesics 
and a tendency towards lower educational level in WP+ patients (Table 1). The 1990-
fibromyalgia tender point criterion (≥11/18) was fulfilled by 7 (29%) of WP+ and 4 (9%) of 
no-WP patients. WP+ patients scored higher on most SPARCC sites as shown in Figure 1S. 
The most common pain sites in WP+ patients were lower extremities, lower back and the 
shoulder girdle (Figure 2S).  
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Compared to patients without baseline colour Doppler (GAUS=0), those with GAUS 
≥1 were older and had worse objective measures including VAS physician, swollen joints, 
dactylitis, CRP, radiographic damage, subacute (GSAUS) and chronic (GCUS) US pathology 
(Table 2). The mCPDAI was higher in patients with GAUS ≥1 while other composite- and 
composite scores were not statistically different  between GAUS groups, neither was the 
frequency of WP+ nor the type of DMARD (Table 2).  
Additional baseline characteristics for WP and GAUS profiles appear in Tables 2S and 3S. 
 
Achievement of ACR20 response (primary outcome): Table 3 shows the prognostic value of 
WP profile and GAUS profile for subsequent treatment response. Rates of 4-month ACR20 
response were comparable for WP+ (25%) and no-WP (27%). Hence, baseline WP profile 
was not a prognostic factor for ACR20 (Table 3). The C-index statistics was 0.51/0.56 in 
simple/adjusted models, implying that prediction is no better than chance. 
ACR20 response was obtained by 19% with baseline GAUS=0 and 31% with GAUS ≥1. 
GAUS profile had no clear prognostic influence on ACR20 s (Table 3). The C-index was 
0.59/0.58 in simple/adjusted models, i.e. slightly better prediction than by chance.  
Similarly, neither baseline WP nor GAUS profile influenced ACR20 response when analysed 
for the “as observed” or “per protocol” populations (Table 4S). 
Achievement of secondary outcome measures: Baseline WP profile was a strong prognostic 
factor for MDA at follow-up. MDA was achieved 0%/20% of WP+/no-WP patients leading to 
markedly higher odds for MDA among no-WP patients (Table 3). The discrepancy in MDA 
between WP categories was largely attributed to differences in reaching the critical level of 
tender joints, enthesitis and HAQ-DI (Table 5S).   
We found no association between WP profile and DAPSA50 or Patient-reported 
Improvement (Table 3). Baseline GAUS was not of prognostic value for any of the secondary 
response measure (Table 3). 
Correlation between baseline WPI and GAUS and ∆DAS28-CRP, ∆DAPSA and ∆mCPDAI: 
Baseline WPI (0 to 19) did not correlate significantly with ∆DAPSA, ∆mCPDAI (Figure 2) or 
∆DAS28-CRP (Figure 3S). Furthermore, we found no correlation between change in these 
composites and in the WPI during treatment (Figure 4S).  
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Baseline GAUS correlated moderately with improvement in DAPSA, mCPDAI (Figure 2) and 
DAS28-CRP (Figure 3S).  
Change- and endpoint values of COS measures according to WP and GAUS profile: Changes 
in the COS measures from baseline to follow-up did not differ significantly between the WP 
or the GAUS profiles (Table 4). 
In ANCOVA models, the enthesitis score (SPARCC) improved less in those presenting with 
WP+ than no-WP (Table 6S). Patients categorised as WP+ at baseline had significantly worse 
COS measures at follow-up including tender joints, enthesitis, pain, disability, fatigue and 
health-related quality, while GAUS profiles showed comparable COS endpoint measures 
except for more swollen joints among GAUS≥1 (Table 7S). 
 
Agreement between WP category at baseline and follow-up: Fifty-five patients had WPI 
information at both time points. Ten out of twenty (50%), who started as WP+ changed to 
no-WP at follow-up, while 4 of 35 (11%) changed from no-WP to WP+. The overall 
agreement on WP category at baseline and follow-up was moderate (Kappa=0.41 [95% CI 
0.16-0.66]). 
 
Baseline characteristics of the secondary pain and US profiles: Patients with PDQ score ≥13 
(n=38), TPC ≥8 (n=17), and SJ/TJ <0.5 (n=47) had worse patient-reported measures including 
higher WPI and more tender joints and entheses compared to the opposite category (Table 
8S-10S). A PDQ score ≥13 was also associated with more inflammatory activity, including 
higher US scores and CRP than patients with PDQ score<13.  
Baseline characteristics for the secondary US categories (GSAUS and GCUS) are 
shown in Table 11S and 12S. The median values used to define these categories were 
GSAUS =16 and GCUS =7. Patients in the high GSAUS and GCUS categories were older, had 
worse swollen joints, pain and quality of life, and for GSAUS more radiographic damage than 
the lower categories. 
 
Prognostic value of secondary pain and US profiles: None of the secondary pain (PDQ, TPC or 
SJ/TJ categories) or US (GSAUS, GCUS) profiles had a significant prognostic value for ACR20 
response (Table 3). However, analyses following peer review showed that the chance of 
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MDA was significantly reduced for patients with high PDQ, low SJ/TJ and especially those 
with TPC≥8 (Table 13S). 
 
DISCUSSION 
The prognostic value of widespread non-arthritic pain 
In the present study, about one-third of PsA patients pragmatically sampled from clinical 
practice presented with widespread non-arthritic pain (WP+), which was associated with 
increased patient-reported  and composite disease scores and significantly reduced chance 
of reaching ‘minimal disease activity’ (MDA) following treatment. 
To our knowledge, this study is the first to show that a WP+ profile, irrespectively of 
fibromyalgia, is a common condition in PsA that influences the evaluation of disease activity 
and treatment outcomes. WP+ was not related to higher baseline PsA activity – neither by 
clinical- nor by ultrasound measures whereas (partially) patient-reported measures and 
thereby composite indices- were significantly worse in WP+ patients. The prognostic impact 
of WP+ differed across the applied outcome measures, which may reflect their different 
weighting of patient-reported domains. Our results indicate that response measures based 
on absolute values for low disease activity, such as the MDA, are more affected by WP+ than 
measures of relative improvement (ACR20, DAPSA50).  
Contributions from central sensitization to generalized pain in RA and OA are well 
documented. (6,7,14,40) Previous studies of pain mechanisms in PsA are scarce, and include 
a few studies that reported lowered pain pressure thresholds in PsA versus healthy controls 
(41) and high frequencies of mixed/neuropathic pain features in PsA according to PDQ, 
similar to our findings (3). Other studies have mainly focused on the worst-end spectrum of 
central sensitization i.e. fibromyalgia. This disorder exists in up to 22% of PsA patients, and 
has by cross-sectional studies been shown to affect measures of PsA activity (10,11,42–44) 
and impair MDA. (11)  
By use of the WPI – and the secondary pain measures – we demonstrated that the 
inability to achieve MDA following anti-rheumatic treatment concerns patients within a 
wider spectrum of central sensitization. 
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The lack of correlation between improvement in WPI and in the composite disease 
activity indices support that WP+ represents a condition of persistent central sensitization 
uncoupled from inflammatory activity. On the other hand, we observed that 50% of patients 
switched from WP+ to no-WP during treatment, and that improvement in ACR20, DAPSA50 
and ∆COS scores were comparable between WP groups. This indicates a reversibility of WP 
in some patients, which could be caused by e.g., 1) natural fluctuation in the severity of 
central sensitization manifestations as described in studies of fibromyalgia, (45) 2) an 
overlap between WPI sites and PsA disease loci that respond to cs/bDMARD therapy, or 3) 
that for some patients, central sensitization is a transient neurophysiological phenomenon 
driven by inflammation. (4) Accordingly, we found that neuropathic/mixed pain features 
(high PDQ) was associated with worse inflammatory PsA activity, as also shown in RA. (46)  
Regardless of what triggers and maintains central sensitization, the condition is 
important to recognize in order to adequately interpret disease measures, ensure sufficient 
pain management, and apply appropriate treatment targets. Our results support that 
feasible patient-reported tools, such as the WPI, could assist the identification of pain 
disorders in routine care of PsA.   
 
The prognostic value of inflammatory activity by colour Doppler 
 We explored the prognostic value of US measures for treatment outcomes and found that 
patients with colour Doppler at baseline(GAUS ≥1) had worse objective disease burden, 
while the patient-reported and composite baseline measures were largely similar to 
patients with GAUS=0. An exception was mCPDAI, which was higher in patients with GAUS 
≥1. Previous cross-sectional studies have found poor/moderate consistency between clinical 
measures and US findings in PsA, and in contrast to our findings reported that DAPSA is 
superior to CPDAI in reflecting US pathology. (16,17) These findings underscore the need to 
further investigate the prognostic value of US in PsA.  
In the present study, none of the US measures were significantly associated to subsequent 
treatment response, whereas studies of RA have shown US to predict response by 
composite outcome measures, (13–15) flares and radiographic progression. (47,48) This 
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could be related to the more uniform/symmetric disease presentation of RA enhancing the 
adequacy of standard US examinations.  
Another reason why baseline US had no impact on response could be the chosen 
dichotomous colour Doppler variable, which is easy to interpret and has been applied in 
previous studies,  (16,49) but does not reflect the continuum of inflammatory activity. As 
seen from the scatter plot, a significant relationship between baseline GAUS (0-30) and 
improvement in DAPSA, DAS28-CRP and mCPDAI at follow-up was evident. Thus, using 
continuous scores or a different categorization could perhaps increase the prognostic value 
of US.  
 
Strengths and limitations 
This study represents a novel approach to investigate pain- and US profiles of PsA patients 
and their prognostic value for treatment response. Strengths include the integration of the 
updated PsA COS, and the application of PsA specific disease/response measures. (1) In 
addition, we strived to optimize the external validity and clinical relevance of the study by 1) 
using a strictly observational design 2) studying prognostic factors of relevance for clinical 
settings, and 3) involving patient-research partners to ensure the patient’s perspective.  
The study has important limitations. The exploratory approach means that results 
must be interpreted with caution. Our definition of central sensitization (WP) as well as the 
applied composite ultrasound scores (GAUS, GSAUS, GCUS) were guided by previous 
studies, but are widely exploratory.   
The 4-month response rates reported in the present study were generally low. A 
reason could be that most patients received csDMARD treatment, which may have low 
efficacy in PsA in general, (50) and perhaps especially in this cohort where 50% had tried 
DMARDs previously. Furthermore, the relatively high drop-out rate decreased the intention 
to treat response rates. 
The relationship between pain profile and measures of disease activity and 
treatment response is likely multifactorial. To optimize treatment strategies, clinicians and 
patients need insight into how pain mechanisms, disease activity, socio-demographic and 
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psychological factors interact and contribute to the overall prognosis. The small sample size 
restricted our possibility to investigate confounding and mediating factors such as smoking, 
obesity, educational level and disease duration, which should gain focus in future studies. 
WP+ patients had higher scores across several SPARCC regions, including those located 
outside joints and tender points, which underscores the need to study the relationship 
between WP and enthesitis in PsA.  
Measurements of the COS domains were pragmatically chosen since a recommended 
set of COS instruments is not yet endorsed by OMERACT. However several of the tools have 
some evidence for good measurement properties in PsA. (51) 
In conclusion, widespread, non-arthritic pain was present in more than a third of patients in 
this PsA cohort. This condition was associated with worse patient-reported and composite 
disease measures, and inability to fulfil the minimal disease activity criteria after 4 months’ 
treatment. Presence of US colour Doppler activity at baseline was associated with more 
severe PsA activity according to objective – but not patient-reported measures. US 
measures had no prognostic value for treatment response in this cohort 
 
Acknowledgement: We wish thank all patients who participated in this study, and the 
patient-research partners. Furthermore, we thank Christian Cato and Peter Krusager for 
support with data management and databases, and all clinical staff involved in the study: 
Sophia Lelakis, Mai-Britt Lundqvist, Christina Christensen, Lene Jensen (sonographer LJ), Jack 
Olsen, Nina Ankerstjerne, Eva Andersen and Line Rustad. We also thank the clinical 
departments for assisting with recruitment of participants. Finally, we wish to thank the 
funding sources: the Oak Foundation, the Danish Rheumatism Association, The Danish 
Psoriasis Association, Department of Rheumatology, Gentofte Hospital, Muskellaboratoriets 
fond, and Robert Wehnerts and Kirsten Wehnerts fond. 
 
 
 
 
A
cc
ep
te
d
 A
rt
ic
le
1. Orbai A-M, Wit M de, Mease P, Shea JA, Gossec L, Leung YY, et al. International patient and 
physician consensus on a psoriatic arthritis core outcome set for clinical trials. Ann Rheum Dis 
2017;76:673–680.  
2. Conaghan P, Strand V, Alten R, Sullivan E, Blackburn S, Huneault L, et al. OP0107 Pain still remains 
a high unmet need among psoriatic arthritis patients receiving existing biologic treatment: results 
from a multi national real-world survey. In: Oral Presentations.Vol 76. BMJ Publishing Group Ltd and 
European League Against Rheumatism; 2017:96.2-97.  
3. Rifbjerg-Madsen S, Christensen AW, Christensen R, Hetland ML, Bliddal H, Kristensen LE, et al. 
Pain and pain mechanisms in patients with inflammatory arthritis: A Danish nationwide cross-
sectional DANBIO registry survey. Klooster PM ten, ed. PLoS One 2017;12:e0180014.  
4. Schaible H-G, Ebersberger A, Banchet GS Von. Mechanisms of pain in arthritis. Ann N Y Acad Sci 
2002;966:343–54.  
5. Wolfe F. Fibromyalgianess. Arthritis Rheum 2009;61:715–716.. 
6. Lee YC, Nassikas NJ, Clauw DJ. The role of the central nervous system in the generation and 
maintenance of chronic pain in rheumatoid arthritis, osteoarthritis and fibromyalgia. Arthritis Res 
Ther 2011;13:211.  
7. Meeus M, Vervisch S, Clerck LS De, Moorkens G, Hans G, Nijs J. Central sensitization in patients 
with rheumatoid arthritis: A systematic literature review. Semin Arthritis Rheum 2012;41:556–67. 
Av017. 
8. Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Häuser W, Katz RL, et al. 2016 Revisions to the 
2010/2011 fibromyalgia diagnostic criteria. Semin Arthritis Rheum 2016;46:319–329. 
9. Woolf CJ. Central sensitization: Implications for the diagnosis and treatment of pain. Pain 
2011;152. 
10. Mease PJ. Fibromyalgia, a missed comorbidity in spondyloarthritis: Prevalence and impact on 
assessment and treatment. Curr Opin Rheumatol 2017;29:304–310.  
11. Brikman S, Furer V, Wollman J, Borok S, Matz H, Polachek A, et al. The effect of the presence of 
fibromyalgia on common clinical disease activity indices in patients with psoriatic arthritis: A cross-
sectional study. J Rheumatol 2016;43:1749–1754.  
12. Wakefield RJ, Balint P V., Szkudlarek M, Filippucci E, Backhaus M, D’Agostino MA, et al. 
Musculoskeletal ultrasound including definitions for ultrasonographic pathology. In: Journal of 
Rheumatology.Vol 32.; 2005:2485–2487. 
13. Porta F, Radunovic G, Vlad V, Micu MC, Nestorova R, Petranova T, et al. The role of doppler 
ultrasound in rheumatic diseases. Rheumatol (United Kingdom) 2012;51:976–982. 
14. Christensen AW, Rifbjerg-Madsen S, Christensen R, Dreyer L, Boesen M, Ellegaard K, et al. 
Ultrasound Doppler but not temporal summation of pain predicts DAS28 response in rheumatoid 
arthritis: A prospective cohort study. Rheumatol (United Kingdom) 2016;55:1091–1098. 
15. Ellegaard K, Christensen R, Torp-Pedersen S, Terslev L, Holm CC, Kønig MJ, et al. Ultrasound 
Doppler measurements predict success of treatment with anti-TNF-α drug in patients with 
rheumatoid arthritis: A prospective cohort study. Rheumatology 2011;50:506–512.  
16. Michelsen B, Diamantopoulos AP, Hammer HB, Soldal DM, Kavanaugh A, Haugeberg G. 
A
cc
ep
te
d
 A
rt
ic
le
Ultrasonographic evaluation in psoriatic arthritis is of major importance in evaluating disease 
activity. Ann Rheum Dis 2016;75:2108–2113.  
17. Husic R, Gretler J, Felber A, Graninger WB, Duftner C, Hermann J, et al. Disparity between 
ultrasound and clinical findings in psoriatic arthritis. Ann Rheum Dis 2014;73:1529–1536.  
18. Højgaard P, Christensen R, Dreyer L, Mease P, Wit M de, Skov L, et al. Pain mechanisms and 
ultrasonic inflammatory activity as prognostic factors in patients with psoriatic arthritis: Protocol for 
a prospective, exploratory cohort study. BMJ Open 2016;6. 
19. Elm E von, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening 
the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting 
observational studies. J Clin Epidemiol 2008;61:344–349. 
20. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H. Classification Criteria for 
Psoriatic Arthritis Development of New Criteria From a Large International Study. ARTHRITIS Rheum 
2006;54:2665–2673.  
21. Freynhagen R, Baron R, Gockel U, Tölle TR. pain DETECT : a new screening questionnaire to 
identify neuropathic components in patients with back pain. Curr Med Res Opin 2006;22:1911–1920. 
22. Wu Q, Inman RD, Davis KD. Neuropathic pain in ankylosing spondylitis: A psychophysics and brain 
imaging study. Arthritis Rheum 2013;65:1494–1503. 
23. Amris K, Jespersen A, Bliddal H. Self-reported somatosensory symptoms of neuropathic pain in 
fibromyalgia and chronic widespread pain correlate with tender point count and pressure-pain 
thresholds. Pain 2010;151:664–669.  
24. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) - a simple practical measure for 
routine clinical use. Clin Exp Dermatol 1994;19:210–216.  
25. Gossec L, Wit M de, Kiltz U, Braun J, Kalyoncu U, Scrivo R, et al. A patient-derived and patient-
reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of 
the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire, a 13-country EULAR initiative. Ann 
Rheum Dis 2014;73:1012–1019.  
26. Thorsen H, Hansen TM, McKenna SP, Sørensen SF, Whalley D. Adaptation into Danish of the 
Stanford Health Assessment Questionnaire (HAQ) and the Rheumatoid Arthritis Quality of Life Scale 
(RAQoL). Scand J Rheumatol 2001;30:103–109. 
27. Pedersen OB, Hansen GO, Svendsen AJ, Ejstrup L, Junker P. Adaptation of the Bath measures on 
disease activity and function in ankylosing spondylitis into Danish. Scand J Rheumatol 2007;36:22–
27. 
28. Bjorner JB, Thunedborg K, Kristensen TS, Modvig J, Bech P. The Danish SF-36 Health Survey: 
Translation and preliminary validity studies. J Clin Epidemiol 1998;51:991–999. 
29. Terslev L, Naredo E, Iagnocco A, Balint P V., Wakefield RJ, Aegerter P, et al. Defining enthesitis in 
spondyloarthritis by ultrasound: Results of a delphi process and of a reliability reading exercise. 
Arthritis Care Res 2014;66:741–748. 
30. Marchesoni A, Atzeni F, Spadaro A, Lubrano E, Provenzano G, Cauli A, et al. Identification of the 
clinical features distinguishing psoriatic arthritis and fibromyalgia. J Rheumatol 2012;39:849–855. 
31. Kristensen LE, Bliddal H, Christensen R, Karlsson JA, Gülfe A, Saxne T, et al. Is swollen to tender 
A
cc
ep
te
d
 A
rt
ic
le
joint count ratio a new and useful clinical marker for biologic drug response in rheumatoid arthritis? 
results from a Swedish cohort. Arthritis Care Res 2014;66:173–179. 
32. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American college of 
rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 
1995;38:727–735. 
33. Coates LC, Helliwell PS. Validation of minimal disease activity criteria for psoriatic arthritis using 
interventional trial data. Arthritis Care Res 2010;62:965–969. 
34. Schoels MM, Aletaha D, Alasti F, Smolen JS. Disease activity in psoriatic arthritis (PsA): Defining 
remission and treatment success using the DAPSA score. Ann Rheum Dis 2016;75:811–818. 
35. Fransen J, Riel PLCM van. The Disease Activity Score and the EULAR response criteria. Clin Exp 
Rheumatol 2005;23:S93–S99. 
36. FitzGerald O, Helliwell P, Mease P, Mumtaz A, Coates L, Pedersen R, et al. Application of 
composite disease activity scores in psoriatic arthritis to the PRESTA data set. Ann Rheum Dis 
2012;71:358–362. 
37. J. Sweeting M, J. Sutton A, C. Lambert P. What to add to nothing? Use and avoidance of 
continuity corrections in meta-analysis of sparse data. Stat Med 2004;23:1351–1375.  
38. Christensen R, Kristensen PK, Bartels EM, Bliddal H, Astrup A. Efficacy and safety of the weight-
loss drug rimonabant: a meta-analysis of randomised trials. Lancet 2007;370:1706–1713. 
39. Royston P, Altman DG. Visualizing and assessing discrimination in the logistic regression model. 
Stat Med 2010;29:2508–2520. 
40. Lluch E, Torres R, Nijs J, Oosterwijck J Van. Evidence for central sensitization in patients with 
osteoarthritis pain: A systematic literature review. Eur J Pain 2014;18:1367–1375.   
41. Bagnato G, Andres I De, Sorbara S, Verduci E, Corallo G, Ferrera A, et al. Pain threshold and 
intensity in rheumatic patients: correlations with the Hamilton Depression Rating scale. Clin 
Rheumatol 2015;34:555–561. 
42. Salaffi F, Angelis R De, Carotti M, Gutierrez M, Sarzi-Puttini P, Atzeni F. Fibromyalgia in patients 
with axial spondyloarthritis: epidemiological profile and effect on measures of disease activity. 
Rheumatol Int 2014;34:1103–10.  
43. Azevedo VF, Paiva E dos S, Felippe LRH, Moreira RA. Occurrence of fibromyalgia in patients with 
ankylosing spondylitis. Rev Bras Reumatol 50:646–50.  
44. Husted J a, Thavaneswaran A, Chandran V, Gladman DD. Incremental effects of comorbidity on 
quality of life in patients with psoriatic arthritis. J Rheumatol 2013;40:1349–1356. 
45. Adams EH, McElroy HJ, Udall M, Masters ET, Mann RM, Schaefer CP, et al. Progression of 
fibromyalgia: Results from a 2-year observational fibromyalgia and chronic pain study in the US. J 
Pain Res 2016;9:325–336. 
46. Rifbjerg-Madsen S, Christensen AW, Boesen M, Christensen R, Danneskiold-Samsøe B, Bliddal H, 
et al. Indications of reversibility of central sensitization according to the paindetect questionnaire in 
patients with rheumatoid arthritis: Results from the prospective frame-cohort study. Ann Rheum Dis 
2016;75:463–464. 
47. Hama M, Uehara T, Takase K, Ihata A, Ueda A, Takeno M, et al. Power Doppler ultrasonography is 
A
cc
ep
te
d
 A
rt
ic
le
useful for assessing disease activity and predicting joint destruction in rheumatoid arthritis patients 
receiving tocilizumab-preliminary data. Rheumatol Int 2012;32:1327–1333. 
48. Saleem B, Brown AK, Quinn M, Karim Z, Hensor EMA, Conaghan P, et al. Can flare be predicted in 
DMARD treated RA patients in remission, and is it important? A cohort study. Ann Rheum Dis 
2012;71:1316–1321. 
49. Ficjan A, Husic R, Gretler J, Lackner A, Graninger WB, Gutierrez M, et al. Ultrasound composite 
scores for the assessment of inflammatory and structural pathologies in Psoriatic Arthritis (PsASon-
Score). Arthritis Res Ther 2014;16:476. 
50. Kingsley GH, Kowalczyk A, Taylor H, Ibrahim F, Packham JC, McHugh NJ, et al. A randomized 
placebo-controlled trial of methotrexate in psoriatic arthritis. Rheumatology 2012;51:1368–1377.  
51. Højgaard P, Klokker L, Orbai A-MA-M, Holmsted K, Bartels EMEM, Leung YYYY, et al. A systematic 
review of measurement properties of patient reported outcome measures in psoriatic arthritis: A 
GRAPPA-OMERACT initiative. Semin Arthritis Rheum 2018; 47:654-665 
 
 
 
 
  
A
cc
ep
te
d
 A
rt
ic
le
Table 1 Baseline characteristics according to pain profile (widespread non-arthritic pain yes/no) 
Demography/Medication WP+ (n=24) No-WP (n=45) Difference1 (95%CI) P-value 
Age, years 51.2 (9.2) 49.9 (15.2) 1.2 (-4.6 to 7.1) 0.675 
Females, n (%) 15 (63) 24 (53) 1.17 (0.78 to 1.77) 0.634 
Higher Education, n (%) 4 (17) 19 (42) 0.39 (0.15 to 1.03) 0.061 
Body mass index, (kg/m2) 27.3 (5.0) 26.0 (5.6) 1.3 (-1.4 to 4.0) 0.343 
Months of PsA, median [IQR] 36 [2 to 124] 6 [1 to 48] 30 (-9 to 93) 0.130 
Months of Pso, median [IQR] 138 [24 to 324] 120 [24 to 384] 18 (-101 to 204) 0.719 
Diagnosed axial PsA, n (%) 3 (13) 7 (16) 0-80 (0.23 to 2.63) 0.999 
Radiographic PsA, n (%) 6 (25) 13 (29) 0.87 (0.38 to 1.99) 0.951 
csDMARD initiator, n (%) 15 (63) 33 (73) 0.85 (0.60 to 1.22) 0.511 
Daily mild analgesics, n (%) 11 (46) 9 (20) 2.29 (1.11 to 4.75) 0.048 
Daily NSAIDs use, n (%) 8 (33)          11 (24)    1.36 (0.64 to 2.93) 0.614 
Daily opioid use, n (%) 3 (13) 0 (0) 9.63 (1.12 to 82.64) 0.039 
Patient-reported measures     
WPI (0-19), median [IQR] 6.0 [4.0 to 9.3] 2.0 [0.0 to 2.0] 4.0 [2.0 to 7.5] <0.001 
VAS global (0-100) 74.7 (17.8) 50.2 (29.7) 24.5 (13.1 to 36.0) <0.001 
VAS Pain (0-100) 68.8 (19.2) 44.5 (27.6) 24.3 (11.7 to 36.9) <0.001 
PainDETECT score (-1 to 38) 18.3 (5.6) 11.3 (6.1) 7.1 (4.1 to 10.1) <0.001 
SF-36 MCS (0-100) 43.5 (14.9) 50.3 (11.0) -6.8 (-13.1 to -0.5) 0.034 
SF-36 PCS (0-100) 28.4 (9.1) 37.9 (9.2) -9.4 (-14.0 to -4.8) <0.001 
PsAID-12 (0-10) 6.2 (1.7) 4.2 (2.2) 2.0 (1.0 to 3.1) <0.001 
DLQI (0-30), median [IQR] 1.0 [1.0 to 4.5] 1.0 [0.0 to 4.0] 0.0 (-1.0 to 1.0) 0.558 
NRS Fatigue (0-10) 7.4 (1.9) 4.7 (2.9) 2.7 (1.5 to 3.9) <0.001 
GAD-10 (0-50), median [IQR] 11.0 [7.8 to 22.0] 6.0 [4.0 to 11.0] 5.0 (2.0 to 11.0) 0.003 
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HAQ-DI (0-3), median [IQR] 1.2 [0.9 to 1.5] 0.6 [0.3 to 1.0] 0.6 (0.3 to 0.9) <0.001 
Clinical/paraclinical measures     
VAS doctor (0-100) 48.2 (17.8) 46.4 (16.9) 1.8 (-6.9 to 10.5) 0.683 
SJC (0-66), median [IQR] 3.0 [1.0 to 6.3] 4.0 [2.0 to 8.0] -1.0 (-4.0 to 2.0) 0.352 
TJC (0-68), median [IQR] 26.5 [24.5 to 37.0] 11.0 [6.0 to 20.0] 15.5 (11.0 to 21.0) <0.001 
SPARCC enthesitis (0-16) 7.5 (3.4) 4.2 (3.0) 3.3 (1.7 to 4.8) <0.001 
DAS28-CRP(0-10) 4.9 (1.0) 3.7 (1.2) 1.1 (0.6 to 1.7) <0.001 
DAPSA (0-164) 49.3 (18.1) 29.8 (18.5) 19.5 (10.2 to 28.7) <0.001 
mCPDAI (0-12) 5.9 (1.2) 4.7 (2.0) 1.2 (0.4 to 2.0) 0.003 
TPC (0-18) median [IQR] 6.0 [3.0 to 12.0] 0.0 [0.0 to 3.0] 6.0 (2.0 to 10.0) <0.001 
PASI (0-72), median [IRQ] 5.4 [3.0 to 8.7] 8.0 [3.0 to 13.3] -2.6 (-6.1 to 2.0) 0.330 
Nail psoriasis, n (%) 13 (54) 25 (56) 0.98 (0.62 to 1.53) 1.000 
Dactylitis, n (%) 4 (17) 16 (36) 0.47 (0.18 to 1.25) 0.163 
CRP (mg/L), median [IQR]  5.0 [2.8 to 6.0] 3.0 [1.0 to 6.0] 2.0 (-0.5 to 3.5) 0.203 
GAUS ≥1, n (%) 13 (54) 29 (64) 0.84 (0.55 to 1.29) 0.566 
GAUS (0-203), median [IQR] 1.0 [0.0 to 4.3] 1.0 [0.0 to 5.0] 0.0 (-3.0 to 3.0) 0.686 
GSAUS (0-204), median [IQR] 17.0 [11.0 to 23.5] 16.0 [8.0 to 23.0] 1.0 (-5.0 to 8.0) 0.335 
GCUS (0-312), median [IQR] 8.5 [2.8 to 11.3] 7.0 [1.0 to 10.0] 1.5 (-4.0 to 5.0) 0.387 
Data presented as mean (SD) unless otherwise stated. Analyses of n=69, except PASI n=56 with BSA>1.
1
Differences in means or medians, 
risk ratios for binary data. CI, confidence interval; csDMARD, conventional synthetic DMARDs; DAPSA, Disease activity Index for PsA; DAS28, 
Disease Activity Score; DLQI, Dermatology Life Quality Index; GAD Generalized Anxiety Disorder, GAUS/GSAUS/GCUS, Global 
acute/subacute/chronic ultrasound score; SF-36 MCS/PCS, Short Form-36 Mental/Physical Component Summary; PASI, Psoriatic Area 
Severity Index; Pso, psoriasis; PsAID, PsA Impact of Disease; SPARCC, SpA Research Consortium of Canada; TPC, tender point count, WPI, 
widespread pain index. 
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Table 2 Baseline characteristics according to ultrasound profiles (colour Doppler activity yes/no) 
Demography/Medication GAUS ≥1 (n=42) GAUS = 0 (n= 27) Difference1(95%CI) P-value 
Age, years 53.2 (12.9) 46.0 (13.1) 7.2 (0.8 to 13.6) 0.027 
Female, n (%) 21 (50) 18 (67) 0.75 (0.50 to 1.12) 0.265 
Higher Education, n (%) 14 (33) 9 (33) 1.00 (0.50 to 1.98) 0.999 
Body mass index (kg/m2) 26.4 (5.1) 26.5 (5.9) -0.1 (-2.8 to 2.6) 0.936 
Months of PsA, median [IQR] 12 [1 to 81] 9 [1 to 84] 3(-48 to 25) 0.930 
Months of Pso, median [IQR] 132 [37 to 381] 100 [3 to 306] 32 (-120 to 200) 0.184 
Diagnosed AxPsA n (%) 5 (12) 5 (19) 0.64 (0.21 to 2.01) 0.681 
Radiographic PsA, n (%) 17 (40) 2 (7) 5.46 (1.37 to 21.79) 0.003 
Scheduled for csDMARD, n (%) 28 (67) 20 (74) 0.90 (0.66 to 1.23) 0.701 
Daily NSAIDs use, n (%) 11 (26) 8 (30) 0.88 (0.41 to 1.91) 0.971 
Daily analgesics use, n (%) 11 (26) 9 (33)  0.79 (0.38 to 1.64) 0.714 
Daily opioid use, n (%) 1 (2) 2 (7) 0.32 (0.03 to 3.37) 0.556 
Patient reported measures     
Widespread pain (WP+), n (%) 13 (31) 11 (41) 0.76 (0.40 to 1.44) 0.556 
VAS global (0-100) 60.4 (27.4) 56.1 (30.7) 4.2 (-9.9 to 18.3) 0.554 
VAS Pain (0-100) 55.5 (27.1) 49.0 (28.0) 6.5 (-7.0 to 20.1) 0.337 
PDQ score (-1 -38) 14.5 (7.6) 12.6 (5.4) 1.9 (-1.4 to 5.3) 0.257 
MOS SF-36 MCS (0-100) 47.9 (13.6) 48.0 (11.8) -0.1 (-6.4 to 6.3) 0.987 
MOS SF-36 PCS (0-100) 34.6 (9.7) 34.6 (10.9) -0.0 (-5.0 to 5.0) 0.994 
PsAID-12 (0-10) 5.1 (2.4) 4.7 (2.2) 0.4 (-0.7 to 1.5) 0.472 
DLQI (0-30) median [IQR] 2.0 [0.3 to 4.0] 1.0 [0.0 to 2.5] 1.0 (0.0 to 2.0) 0.179 
NRS Fatigue (0-100) 5.7 (3.0) 5.6 (2.8) 0.1 (-1.4 to 1.5) 0.933 
GAD-10 (0-50) median [IQR] 6.5 [5.0 to 12.5] 9.0 [5.0 to 17.5] -2.5 (-9.5 to 2.0) 0.365 
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HAQ-DI (0-3) median [IQR] 0.9 [0.5 to 1.3] 0.8 [0.3 to 1.0] 0.2 (-0.1 to 0.6) 0.126 
Clinical/composite measures     
VAS doctor (0-100) 52.0 (15.3) 39.3 (17.3) 12.7 (4.7 to 20.6) 0.002 
SJC (0-66) median [IQR] 6.0 [2.0 to 9.0] 3.0 [1.0 to 5.0] 3.0 (0.0 to 6.0) 0.012 
TJC (0-68) median [IQR] 16.5 [7.3 to 26.8] 15.0 [7.5 to 29.0] 1.5 (-12.5 to 12.0) 0.892 
SPARCC enthesitis (0-16) 5.5 (3.7) 5.2 (3.3) 0.3 (-1.4 to 2.0) 0.717 
DAS28CRP score (0-10) 4.3 (1.2) 3.9 (1.4) 0.4 (-0.2 to 1.1) 0.174 
DAPSA score (0-164) 38.4 (21.0) 33.8 (19.8) 4.6 (-5.5 to 14.7) 0.366 
mCPDAI (0-12) 5.5 (2.0) 4.5 (1.5) 0.9 (0.0 to 1.8) 0.039 
TPC (0-18) 1.5 [0.0 to 4.8] 4.0 [0.0 to 9.0] -2.5 (-6.0 to 0.5) 0.174 
PASI (0-72) median [IQR] 7.0 [3.1 to 12.0] 5.0 [2.8 to 11.8] 2.1 (-3.5 to 5.0) 0.499 
Nail psoriasis, n (%) 21 (50) 17 (63) 0.79 (0.52 to 1.21) 0.419 
Dactylitis n (%) 17 (40%) 3 (11%)  3.64 (1.18 to 11.26) 0.013  
CRP level, mg/L median [IQR] 5.0 [2.0 to 9.0] 2.0 [1.0 to 4.0] 3.0 (0.0 to 4.0) 0.010 
GSAUS (0-204), median [IQR] 22.0 [14.0 to 27.8] 9.0 [6.0 to 15.5] 13.0 (5.5 to 16.0) <0.001 
GCUS (0-312), median [IQR] 8.0 [3.3 to 14.8] 4.0 [1.0 to 8.5] 4.0 (0.0 to 7.0) 0.015 
Data presented as mean (SD) unless otherwise stated. Analyses included n=69, except PASI (n=56 with BSA>1).
1
Differences 
in means or medians, risk ratios for binary data. CI, confidence interval; csDMARD, conventional synthetic disease modifying 
anti-rheumatic drugs; DAPSA, Disease activity Index for PsA; DAS28, Disease Activity Score; DLQI, Dermatology Life Quality 
Index; GAD Generalized Anxiety Disorder, GAUS/GSAUS/GCUS, Global acute/subacute/chronic ultrasound scores; HAQ-
DI,Health Assessment Questionnaire disability index; SF-36 MCS/PCS, Short Form-36 Mental/Physical Component Summary; 
PASI, Psoriatic Area Severity Index; Pso, psoriasis; PsAID, PsA Impact of Disease; SPARCC, SpA Research Consortium of 
Canada; TPC, tender point count.  
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Table 3: Prognostic value of pain- and ultrasound (US) profiles for treatment response 
Prognostic 
 
   Responders  Simple model 
 
Adjusted model1 
Factors n      n (%) OR (95%CI) P-value        OR (95%CI) P-value 
Primary       ACR20 response    
WP+ 24  6 (25) [Reference level]  [Reference level]  
No-WP 45 12 (27) 1.09 (0.36 to 3.58) 0.880 1.07 (0.35 to 3.53) 0.912 
GAUS =0 27 5 (19) [Reference level]  [Reference level]  
GAUS ≥1 42 13 (31) 1.97 (0.64 to 6.90) 0.244 1.86 (0.57 to 6.84) 0.313 
Primary                              Minimal Disease activity  
WP+ 24 0 (0) [Reference level] 
 
[Reference level] 
 No-WP 45 9 (20) 18.43 (1.51 to 224.41)1 0.022 NE NE 
GAUS =0 27 3 (11) [Reference level] 
 
[Reference level] 
 GAUS ≥1 42 6 (14) 1.33 (0.32 to 6.80) 0.700 1.84 (0.39 to 10.73) 0.447 
Primary                               DAPSA 50%    
WP+ 24 7 (29) [Reference level] 
 
[Reference level] 
 No-WP 45 15 (33) 1.21 (0.42 to 3.72) 0.723 1.15 (0.39 to 3.56) 0.806 
GAUS =0 27 7 (26) [Reference level] 
 
[Reference level] 
 GAUS ≥1 42 15 (36) 1.59 (0.56 to 4.83) 0.391 1.49 (0.49 to 4.83) 0.483 
Primary                             Patient-reported improvement  
WP+ 24 10 (42) [Reference level] 
 
[Reference level] 
 No-WP 45 18 (40) 0.93 (0.34 to 2.59) 0.893 0.94 (0.34 to 2.66) 0.913 
GAUS =0 27 8 (30) [Reference level] 
 
[Reference level] 
 GAUS ≥1 42 20 (48) 2.16 (0.79 to 6.25) 0.134 2.81 (0.95 to 9.16) 0.062 
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Secondary        ACR20 response    
PDQ ≥13 38 9 (24) [Reference level]  [Reference level]  
PDQ <13 31 9 (29) 1.32 (0.44 to 3.92) 0.615 1.42 (0.47 to 4.33) 0.534 
TPC ≥8 17 3 (18) [Reference level]  [Reference level]  
TPC <8 52 15 (29) 1.89 (0.52 to 9.06) 0.347 1.73 (0.45 to 8.52) 0.439 
SJ/TJ2 <0.5 47 11 (28) [Reference level]  [Reference level]  
SJ/TJ ≥0.5 21 6 (29) 1.31 (0.39 to 4.13) 0.652 1.20 (0.35 to 3.89) 0.764 
GSAUS <163 32 6 (19) [Reference level]  [Reference level]  
GSAUS ≥16 37 12 (32) 2.08 (0.70 to 6.77) 0.193 2.02 (0.60 to 7.45) 0.261 
GCUS <73 39 9 (23) [Reference level]  [Reference level]  
GCUS ≥7 30       9 (30) 1.43 (0.48 to 4.26)   0.517   2.07 (0.55 to 8.39)  0.285 
Intention to treat analyses. 
1
Logistic regression adjusted for age and gender. 
2
One patients not included due to zero SJ and TJ, patients with 0 
SJ and ≥2 TJ were coded as SJ/TJ <0.5 (n=7), and 0 TJ and ≥ 1 SJ as SJ/TJ ≥0.5 (n=2). 
3
Median values used as cut-offs. DAPSA, Disease Activity 
Index for PsA; GAUS/GSAUS/GCUS, Global Acute/Subacute/Chronic Ultrasonic Score; NE, not estimable; PDQ; PainDetect Questionnaire 
score; TPC; Tender point count; SJ/TJ swollen/tender joints ratio; WP, widespread non-arthritic pain. 
1
A continuity correction was used to 
calculate the OR as explained in Methods.   
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Table 4 Change in PsA core domains from baseline to follow-up for WP and GAUS groups 
COS1 measures WP+ (n=24) No-WP (n=45) Difference (95%CI)           P-value 
∆SJC, median [IQR] -0.5 [-5.0 to 0.0] -1.0 [-4.0 to 0.0] 0.5 (-3.5 to 2.0) 0.863 
∆TJC, median [IQR] -6.5 [-17.5 to 0.0] 0.0 [-8.0 to 0.0] -6.5 (-14.0 to 1.5) 0.071 
∆SPARCC enthesitis -0.3 (0.8) -0.6 (0.4) 0.3 (-1.5 to 2.0) 0.742 
∆PASI, median [IQR] 0.0 [-4.9 to 0.3] 0.0 [-6.5 to 0.0] 0.0 (-3.3 to 3.0) 0.392 
∆VAS pain -16.5 (5.9) -6.6 (3.5) -9.9 (-22.7 to 2.9) 0.127 
∆SF-36 BP, median[IQR] 9.0 [0.0 to 20.3] 0.0 [0.0 to 20.0] 9.0 (-6.0 to 11.0) 0.555 
∆HAQ-DI, median [IQR] 0.0 [-0.4 to 0.0] 0.0 [-0.2 to 0.0] 0.0 (-0.2 to 0.3) 0.401 
∆SF-36 PF 7.7 (3.3) 5.1 (2.2) 2.6 (-5.2 to 10.4) 0.507 
∆DLQI, median [IQR] 0.0 [-1.0 to 0.3] 0.0 [-1.0 to 0.0] 0.0 (0.0 to 0.0) 0.787 
∆PsAID -1.1 (0.4) -0.9 (0.3) -0.2 (-1.3 to 0.9) 0.691 
∆Patient Global VAS -20.3 (5.5) -9.9 (4.0) -10.4 (-23.8 to 3.0) 0.126 
∆NRS Fatigue -0.9 (0.5) -0.5 (0.3) -0.4 (-1.6 to 0.8) 0.487 
∆SF-36 VT 6.0 (4.4) 3.1 (2.4) 2.9 (-6.3 to 12.2) 0.528 
∆CRP, median [IQR] -2.0 [-4.0 to 0.0] 0.0 [-2.0 to 0.0] -2.0 (-3.0 to 0.0) 0.059 
COS1 measures GAUS=0 (n=27) GAUS ≥1 (n=42) Difference (95%CI) P-value 
∆SJC, median [IQR] 0.0 [-3.0 to 0.0] -1.5 [-4.7 to 0.0] 1.5 (-1.0 to 3.0) 0.476 
∆TJC, median [IQR] 0.0 [-7.5 to 0.0] -5.0 [-13.2 to 0.0] 5.0 (-3.0 to 9.0) 0.236 
∆SPARCC enthesitis 0.1 (0.6) -0.9 (0.5) 1.0 (-0.7 to 2.7) 0.250 
∆PASI, median [IQR] 0.0 [-1.5 to 0.0] -1.7 [-6.9 to 0.0] 1.8 (0.0 to 5.5) 0.111 
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∆VAS pain -5.5 (3.5) -13.0 (4.5) 7.5 (-4.0 to 18.9) 0.196 
∆SF-36 BP, median[IQR] 0.0 [0.0 to 15.5] 0.0 [0.0 to 20.0] 0.0 (-10.0 to 10.0) 0.786 
∆HAQ-DI, median [IQR] 0.0 [-0.1 to 0.0] -0.1 [-0.4 to 0.0] 0.1 (0.0 to 0.3) 0.172 
∆SF-36 PF 3.3 (2.4) 7.7 (2.6) -4.4 (-11.9 to 3.1) 0.247 
∆DLQI, median [IQR] 0.0 [0.0 to 0.5] 0.0 [-1.0 to 0.0] 0.0 (0.0 to 0.5) 0.127 
∆PsAID -0.7 (0.3) -1.2 (0.4) 0.5 (-0.5 to 1.5) 0.315 
∆Patient Global VAS -10.7 (3.8) -15.4 (4.7) 4.7 (-7.4 to 16.8) 0.441 
∆NRS Fatigue -0.3 (0.5) -0.8 (0.3) 0.5 (-0.7 to 1.6) 0.430 
∆SF-36 VT 3.3 (3.2) 4.6 (3.0) -1.3 (-10.3 to 7.7) 0.773 
∆CRP, median [IQR] 0.0 [-2.0 to 0.0] 0.0 [-5.7 to 0.0] 0.0 (-1.0 to 2.5) 0.177 
Data are presented as mean (SE) unless otherwise stated, analyses of ITT data. 
1
OMERACT Core Outcome Set for PsA. BP, Bodily Pain; CI, 
confidence interval; DLQI, Dermatology Life Quality Index; HAQ-DI, Health Assessment Questionnaire Disability Index; NRS, Numeric 
rating scale; PASI, Psoriatic Area Severity Index; PF, Physical Func-tion; PsAID, Psoriatic Arthritis Impact of Disease score; SF-36, Medical 
Outcomes Study Short Form; SJC, swollen joint count; SPARCC, Spondyloarthritis Research Consortium of Canada enthesitis score; TJC, 
tender joint count; WP,widespread non-arthritic  pain; VT, Vitality. 
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